SCHEMBL8428005

SCHEMBL8428005

CC1(C)CC(=O)C(=CNc2ccc(O)cc2)C(=O)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.51
▸ MEN1 O00255 7/20 0.51
▸ KMT2A Q03164 7/20 0.51
▸ KDM4E B2RXH2 7/20 0.51
▸ L3MBTL1 Q9Y468 5/20 0.51
▸ LMNA P02545 4/20 0.51
▸ POLB P06746 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ PLEC Q15149 1/20 0.51
▸ ALDH1A1 P00352 14/20 0.50
▸ GAA P10253 4/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ THRB P10828 2/20 0.50
▸ ALOX12 P18054 2/20 0.50
▸ RECQL P46063 2/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ HPGD P15428 2/20 0.43
▸ CASP1 P29466 2/20 0.43
▸ RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12830161 0.85 ALDH1A1 (0.43) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL13640138 0.85 KMT2A (0.49) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL13640141 0.84 ALDH1A1 (0.60) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL22057718 0.84 MAOA (0.45) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL13640189 0.84 NTRK3 (0.43) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL13640144 0.84 ALDH1A1 (0.42) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL11109819 0.83 ALDH1A1 (0.60) MAPTKMT2AL3MBTL1LMNAALDH1A1
SCHEMBL12830162 0.83 RAB9A (0.43) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL12316747 0.81 ALDH1A1 (0.40) MAPTMEN1KMT2AKDM4EL3MBTL1
SCHEMBL8114885 0.81 HSD17B10 (0.53) MAPTMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11180935-A — — None — — JP disclosed
EP-2477491-B1 PLANT ADDITIVES AND USES THEREOF TO MODULATE THE SYNTHESIS OF MEMBRANE GLYCEROLIPIDS IN PLANTS COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-05-17 — — EP disclosed
US-9028855-B2 Plant additives and uses thereof to modulate the synthesis of membrane glycerolipids in planta COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-05-12 — — US disclosed
US-9028855-B2 Plant additives and uses thereof to modulate the synthesis of membrane glycerolipids in planta COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-05-12 — — US disclosed
US-20120283101-A1 Plant Additives and Uses Thereof to Modulate the Synthesis of Membrane Glycerolipids in Planta COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2012-11-08 — — US disclosed
US-20120283101-A1 Plant Additives and Uses Thereof to Modulate the Synthesis of Membrane Glycerolipids in Planta COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2012-11-08 — — US disclosed
JP-H11180935-A AMINOMETHYLENECYCLOHEXANE DERIVATIVE, ITS PRODUCTION AND USE CHEMIPROKASEI KAISHA LTD 1999-07-06 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283101-A1 Plant Additives and Uses Thereof to Modulate the Synthesis of Membrane Glycerolipids in Planta PGM2, SGMS2, PHOSPHO1 MAPT 4242/4885MEN1 2145/4885KMT2A 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback